| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Carolina Schneider, Efstathios Papachristou, Theresa Wimberley, Christiane Gasse, Danai Dima, James H MacCabe, Preben Bo Mortensen, Sophia Frango. Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 6. 2016-02-16. PMID:25769917. |
this study aimed to identify the predictors of clozapine use in eos and characterize the clinical profile and outcome of clozapine-treated youths with schizophrenia. |
2016-02-16 |
2023-08-13 |
Not clear |
| Carolina Schneider, Efstathios Papachristou, Theresa Wimberley, Christiane Gasse, Danai Dima, James H MacCabe, Preben Bo Mortensen, Sophia Frango. Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 6. 2016-02-16. PMID:25769917. |
we identified 662 eos cases (1.9% of all schizophrenia cases), of whom 108 (17.6%) had commenced clozapine by december 31st 2008. |
2016-02-16 |
2023-08-13 |
Not clear |
| Carolina Schneider, Efstathios Papachristou, Theresa Wimberley, Christiane Gasse, Danai Dima, James H MacCabe, Preben Bo Mortensen, Sophia Frango. Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 6. 2016-02-16. PMID:25769917. |
older age at diagnosis of schizophrenia [hr=1.2, 95% ci (1.05-1.4), p=0.01], family history of schizophrenia [hr=2.1, 95% ci (1.1-3.04), p=0.02] and attempted suicide [hr=1.8, 95% ci (1.1-3.04), p=0.02] emerged as significant predictors of clozapine use. |
2016-02-16 |
2023-08-13 |
Not clear |
| A Wysokiński, M L Kowalski, I Kłoszewsk. Serum levels of PYY(1-36) peptide in patients with schizophrenia on clozapine monotherapy. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:24936806. |
serum levels of pyy(1-36) peptide in patients with schizophrenia on clozapine monotherapy. |
2016-02-15 |
2023-08-13 |
Not clear |
| A Wysokiński, M L Kowalski, I Kłoszewsk. Serum levels of PYY(1-36) peptide in patients with schizophrenia on clozapine monotherapy. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:24936806. |
the present study was undertaken to determine if patients with schizophrenia on clozapine monotherapy have lower serum levels of peptide yy [pyy(1-36)], which is an endogenous inhibitor of food intake, comparing to healthy controls. |
2016-02-15 |
2023-08-13 |
Not clear |
| S R T Veerman, P F J Schulte, L de Haa. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:25002292. |
glutamate agonists combined with non-clozapine antipsychotics and glutamate antagonists augmented to clozapine show interesting clinical benefits in refractory schizophrenia. |
2016-02-15 |
2023-08-13 |
Not clear |
| S R T Veerman, P F J Schulte, L de Haa. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry. vol 47. issue 4-5. 2016-02-15. PMID:25002292. |
we illustrate how unique properties of the nmda receptor antagonist memantine in addition to clozapine, may cause improvement of positive, negative and cognitive symptoms of schizophrenia. |
2016-02-15 |
2023-08-13 |
Not clear |
| Kelan L Thomas, Yawen Jiang, Jeffrey S McComb. Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 27. issue 2. 2016-02-15. PMID:25696785. |
clozapine revisited: impact of clozapine vs olanzapine on health care use by schizophrenia patients on medicaid. |
2016-02-15 |
2023-08-13 |
Not clear |
| Kelan L Thomas, Yawen Jiang, Jeffrey S McComb. Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 27. issue 2. 2016-02-15. PMID:25696785. |
our purpose was to evaluate health care use and cost patterns for clozapine compared with olanzapine in the treatment of schizophrenia. |
2016-02-15 |
2023-08-13 |
Not clear |
| William T O'Connor, Sean D O'She. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. Pharmacology & therapeutics. vol 150. 2016-02-08. PMID:25585121. |
clozapine and gaba transmission in schizophrenia disease models: establishing principles to guide treatments. |
2016-02-08 |
2023-08-13 |
Not clear |
| William T O'Connor, Sean D O'She. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. Pharmacology & therapeutics. vol 150. 2016-02-08. PMID:25585121. |
here we summarise the evidence for a gaba dysfunction in schizophrenia and review the functional neuroanatomy of five pathways implicated in schizophrenia, namely the mesocortical, mesolimbic, ventral striopallidal, dorsal striopallidal and perforant pathways including the role of local gaba transmission and we describe the effect of clozapine on local neurotransmitter release. |
2016-02-08 |
2023-08-13 |
Not clear |
| William T O'Connor, Sean D O'She. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. Pharmacology & therapeutics. vol 150. 2016-02-08. PMID:25585121. |
the review concludes that while no single animal model is entirely successful in reproducing schizophreniform symptomatology, a disease model based on an ability to prevent and/or reverse the abrupt clozapine discontinuation-induced changes in gaba release in brain regions implicated in schizophrenia may be useful for hypothesis testing and for in vivo screening of novel ligands not limited to a single pharmacological class. |
2016-02-08 |
2023-08-13 |
Not clear |
| Natalie Hyde, Seetal Dodd, Kamalesh Venugopal, Christa Purdie, Michael Berk, Adrienne O'Nei. Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study. Current drug safety. vol 10. issue 2. 2016-02-08. PMID:25986036. |
the efficacy of clozapine for the treatment of schizophrenia has been demonstrated. |
2016-02-08 |
2023-08-13 |
Not clear |
| Valerie M Anderson, Meghan E Goldstein, Robert R Kydd, Bruce R Russel. Extensive gray matter volume reduction in treatment-resistant schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 7. 2016-02-05. PMID:25716781. |
approximately one-third of people with schizophrenia are treatment-resistant and some do not achieve remission with clozapine, the gold-standard antipsychotic medication for treatment-resistant schizophrenia. |
2016-02-05 |
2023-08-13 |
Not clear |
| S V Sathish Kumar, Vinod Kumar Sinh. Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Indian journal of psychiatry. vol 57. issue 4. 2016-01-28. PMID:26816428. |
comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. |
2016-01-28 |
2023-08-13 |
Not clear |
| Sourav Khanra, Rati Ranjan Sethy, Sanjay Kumar Munda, Christoday Raja Jayant Khes. An Unusual Case of Delirium after Restarting Clozapine. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 14. issue 1. 2016-01-21. PMID:26792049. |
clozapine is a gold standard medication and drug of choice in refractory schizophrenia. |
2016-01-21 |
2023-08-13 |
Not clear |
| Sourav Khanra, Rati Ranjan Sethy, Sanjay Kumar Munda, Christoday Raja Jayant Khes. An Unusual Case of Delirium after Restarting Clozapine. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 14. issue 1. 2016-01-21. PMID:26792049. |
we here present a case of delirium which emerged during retreatment with clozapine in a patient of paranoid schizophrenia. |
2016-01-21 |
2023-08-13 |
Not clear |
| Sandeep Grover, Swapnajeet Saho. Clozapine induced akathisia: a case report and review of the evidence. Indian journal of pharmacology. vol 47. issue 2. 2016-01-15. PMID:25878393. |
clozapine is a second-generation antipsychotic medication, which is mostly used in patients with treatment resistant schizophrenia. |
2016-01-15 |
2023-08-13 |
Not clear |
| Meghan Elizabeth Goldstein, Valerie Margaret Anderson, Avinesh Pillai, Robert R Kydd, Bruce R Russel. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 6. 2016-01-12. PMID:25603859. |
according to the current schizophrenia treatment guidelines, 3 levels of responsiveness to antipsychotic medication exist: those who respond to first-line antipsychotics, those with treatment-resistant schizophrenia who respond to clozapine, and those with clozapine-resistant or ultra-treatment resistant schizophrenia. |
2016-01-12 |
2023-08-13 |
Not clear |
| Florence Elizabeth Chamberlain, Nicholas Walsh, Jan Falkowsk. Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005. BJPsych bulletin. vol 39. issue 6. 2016-01-12. PMID:26755992. |
chemotherapy for hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the mental capacity act 2005. |
2016-01-12 |
2023-08-13 |
Not clear |